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United Kingdom population. [19] Prescription data are automatically recorded when prescriptions are issued, and they are classified according to the British National Formulary (BNF). [20, 21] Significant medical events are recorded by clinicians and coded using the Read system. [22] Data on contact with secondary-care and socio-demographic status are also available. THIN is broadly representative of the UK population and captures valid and complete data. [23] [24] [25] [26] [27] 
Study design
We analysed a retrospective cohort of women who were linked to their live-born children using deterministic (exact) linkage methods. The following variables were considered when linking mothers and children: family ID number, mother's actual or estimated date of delivery, child's month and/or year of birth, and gestational age at delivery/birth.
Participants
Inception to the cohort was restricted to women aged 15-50 years between January 1990 and May 2010, who had registered at their primary-care practice before pregnancy and who had a singleton, child born at or after term (37 weeks of gestation or more). Where gestational age at delivery was uncertain and evidence of pre-or post-term birth was lacking (37%), we assumed pregnancy lasted 40 weeks. For women with multiple pregnancies (approximately 24% in the cohort), we randomly selected one pregnancy for analysis. Children born preterm were excluded because their increased risk of cerebral palsy and epilepsy (related to prenatal, perinatal and postnatal risk factors) could mask any association with antibiotic prescribing in pregnancy. For consistency with the OCS II study [12] , follow-up ended at the earliest of seven completed years of age, the date the child left their primary-care practice, death, or the end of the study (May 2010).
Antibiotic prescriptions
We considered women as treated if they had a prescription record between the last menstrual period and estimated delivery date for any antibiotic in chapter 5.1 of the British National Formulary (BNF), excluding those with topical formulations such as antibiotics used to treat acne (BNF chapter 13.6.1) and conjunctivitis (BNF chapter 11.3.1). A list of the generic antibiotics considered is provided in S1 Appendix-Codes used to identify women with antibiotic prescriptions in pregnancy. All other women were considered as untreated. Antibiotics prescribed and dispensed by hospitals are not captured in THIN, but are likely to affect very few women in this study. Except for women whose illness or labour requires hospital care, treatment would normally be prescribed by the primary-care practitioner. Intrapartum antibiotic prescribing has been estimated to involve less than 5% of women, including those delivering preterm. [28] Cerebral palsy or epilepsy
The pre-specified primary outcome was cerebral palsy and/or epilepsy recorded in a child's primary-care record up to seven years old. We grouped cerebral palsy and epilepsy for the following reasons: 1. they often co-occur; 2. they have common prenatal aetiologies; 3. they were associated with prenatal antibiotic prescribing in the OCS II study; and 4. to increase statistical power for our analyses of timing, number of courses and type of antibiotic prescribed.
We used a previously published and validated algorithm to identify children with epilepsy which was based on one or more codes for an epilepsy diagnosis, symptoms (multiple seizure records), and on-going treatment (repeated prescriptions for anti-epileptic drugs). [29] Further details, and code lists, are provided in S2 Appendix-Description of algorithm and codes used to identify children with epilepsy. A similar algorithm was developed to identify children with cerebral palsy, whereby codes for diagnoses, symptoms (e.g. spasticity), treatment (e.g. intramuscular injection of baclofen) and management procedures (e.g. tenotomy) were used to identify children with possible cerebral palsy. We then reviewed the full medical records of all children with possible cerebral palsy and excluded (from consideration as a child with cerebral palsy) those without consistent evidence of a non-progressive motor disorder. All reviewers were blinded as to whether a child's mother was prescribed antibiotics during pregnancy. Additional details are available in S3 Appendix-Description of algorithm and codes used to identify children with cerebral palsy.
The outcome date was the earliest date upon which evidence for cerebral palsy or epilepsy was recorded.
Maternal risk factors for both antibiotic prescribing in pregnancy and cerebral palsy and/or epilepsy in the child
We classified the following maternal risk factors: maternal age at delivery, pregnancy complications (e.g. any record indicating hypertension or diabetes), chronic conditions (e.g. obesity prior to pregnancy [BMI30 or Read code for obesity], treatment for chronic medical conditions during pregnancy) [30] , behaviours (e.g. recent smoking/tobacco use, alcohol or illicit drug misuse at any time), social deprivation (measured by the Townsend score quintile where Q1 is most affluent and Q5 is most deprived [31] ), maternal infection that was a potentially neurologically-damaging infection (PNDI) for the fetus (e.g. UTIs and chorioamnionitis; see S4 Appendix-Read codes used to identify women with potentially neurologically-damaging infections in pregnancy). [32, 33] These maternal risk factors were chosen a priori based on evidence from the literature of associations between these factors and both our exposure and outcomes of interest. We assumed that absence of codes for maternal conditions indicated absence of those conditions.
Analysis
We used a series of Cox regression models to compare the time to cerebral palsy and/or epilepsy in different groups of women who were and were not prescribed antibiotics in pregnancy. In the primary analysis we compared children whose mothers received one or more antibiotic prescriptions with those whose mothers had no recorded antibiotic prescription. Adjustment was made for potential maternal confounders using the propensity score for antibiotic prescribing. This was derived using all maternal risk factors (for antibiotic prescribing and for having a child with cerebral palsy and/or epilepsy) listed previously as well as calendar year of delivery. [34] Ten women with non-overlapping propensity score distributions were trimmed from the analysis cohort. We further adjusted this and all other analyses for potential clustering at the level of primary-care practice by using robust standard errors. Assumptions of proportional hazards were met for this and all other models.
In a sensitivity analysis (designed to minimise bias due to the type of infection for which antibiotics were prescribed-not to minimise bias due to infection severity) we repeated the above analysis using a restricted cohort which included women with a single respiratory tract infection recorded in pregnancy and compared children whose mothers received an antibiotic prescription for a respiratory tract infection with children whose mothers were not prescribed antibiotics for their respiratory tract infection. Women with respiratory tract infections in pregnancy were identified using Read codes-details are provided in S5 Appendix-Read codes used to identify women with respiratory tract infections in pregnancy.
In secondary analyses we determined the effect of number, timing and type of antibiotic prescriptions in pregnancy on the time to cerebral palsy and/or epilepsy. To assess the effect of number of courses of antibiotics prescribed (where each separate prescription was defined as a single course), we categorised the variable for antibiotic treatment into a four-level variable (none, one, two or three or more courses). We determined the association with the class (type) and timing of antibiotic prescription in analyses restricted to women prescribed a single course of antibiotics. Class of antibiotic was grouped according to BNF sub-chapters (e.g. penicillins, aminoglycosides, macrolides, tetracyclines). Pencillins were chosen as the referent group because they were the most commonly prescribed class of antibiotics in pregnancy and have the longest history of safe use in pregnancy. To assess timing, we categorised prescriptions within four week periods (lunar month) of gestational age. Here, the first lunar month was arbitrarily chosen as the referent group. In all secondary analyses, we accounted for potential confounding using a stepwise approach to model building, as propensity scores are only valid with binary exposure variables. Numbers needed to harm were estimated at age seven years using methods of Altman et al. [35] Finally, in post-hoc analyses requested by a reviewer, we repeated the primary analysis (any versus no antibiotic) and one secondary analysis (class of antibiotic versus penicillins) on risk of epilepsy.
All authors designed the study. WM performed the analyses, with input and advice from RG. Code lists were reviewed by GPs, a paediatrician (RG), and an epileptologist.
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RESULTS
We identified a cohort of 195,909 women linked to their singleton children born at or after term. The cohort comprised all mother-child pairs in THIN meeting the study eligibility criteria. The children were followed up from birth for a median of 3.6 years (inter quartile range [IQR] 1.5-7.2). Median follow-up differed by outcome status-children with cerebral palsy and/or epilepsy were followed-up for 6.5 years (IQR 3.5-10.3) whilst children without were followed-up for 3.7 years (IQR 1.6-7.2). In total, 1,170 (0.6%) children had evidence of cerebral palsy (n = 232), epilepsy (n = 874) or both (n = 64) in their medical records, and 64,623 (33%) were prescribed antibiotics during pregnancy.
Compared to women not prescribed antibiotics, women prescribed antibiotics (Table 1) were on average more deprived, more likely to be obese (15.5% vs 10.9%), to receive treatment for chronic medical conditions in pregnancy (14.9% vs 9.2%), to have problems with alcohol (1.7% vs 1.1%) to use tobacco (28.6% vs 21.5%) or illicit drugs (1.6% vs 0.9%), and to have an infection which could potentially cause fetal neuro-damage (23.2% vs 4.2%).
Unadjusted analyses showed an increased risk of cerebral palsy and/or epilepsy in children born to women prescribed antibiotics compared with women with no recorded prescriptions ( Table 2 : unadj. hazard ratio [HR] 1.20; 95%CI 1.06-1.35; p = 0.004). However, after adjusting for potential confounders, no significant association was evident (adj.HR 1.04; 95% CI 0.91-1.19; p = 0.5). In sensitivity analyses restricted to women with a single respiratory tract infection in pregnancy, no association (significant at the 5% level) was found between antibiotic prescribing and cerebral palsy or epilepsy ( Table 2 ). The post-hoc analysis for epilepsy also showed no significant association between any antibiotic prescribing during pregnancy and the risk of epilepsy in childhood, after adjusting for potential confounders (adj.HR 1.03; 95%CI 0.89-1.10; p = 0.7).
Whilst we found no association with the timing of antibiotic prescription and cerebral palsy or epilepsy, we found that children whose mothers received 3+ prescriptions during pregnancy had a 40% increased risk (adj.HR 1.40; 95%CI 1.07-1.83; p = 0.01) compared to those with no prescriptions (Table 3 ). The incidence of cerebral palsy or epilepsy in children whose mothers received 3+ prescriptions in pregnancy was 261.1 (95%CI 210.5-323.7) per 100,000 childyears-at-risk (CYAR) compared to 143.8 (95%CI 133.8-154.5) in children whose mothers received no prescriptions. The number needed to harm was 291 (95%CI 141-191) at age seven years. Children whose mothers were prescribed macrolides had a 78% increased risk (adj.HR 1.78; 95%CI 1.18-2.69; p = 0.006) compared to those prescribed penicillins ( Table 3 ). The incidence of cerebral palsy or epilepsy in children whose mothers were prescribed macrolides was 254.6 per 100,000 CYAR (95%CI 175.6-368.3) compared to 143.6 (95%CI 122.8-169.0) in children whose mothers were prescribed penicillin. The number need to harm was 153 (95%CI 71-671) at age seven years. The post-hoc analysis which looked at epilepsy as the outcome, found that macrolide versus penicillin prescribing in pregnancy was associated with a doubling in the risk of epilepsy in childhood (adj.HR 2.02; 95%CI 1.30-3.14; p = 0.002).
DISCUSSION
We found no evidence for an increased risk of cerebral palsy and/or epilepsy in children of women prescribed any antibiotics in pregnancy compared with no antibiotics after taking into account maternal risk factors for treatment. Children of women prescribed three courses or more of antibiotics compared with none did have an increased risk of cerebral palsy or epilepsy which may reflect the risks associated with recurrent infections. We also found an increased risk of cerebral palsy or epilepsy in children of women prescribed macrolides compared with penicillins.
Strengths of our study are the large cohort, the fact that THIN captures all primary-care prescribing (though not dispensing), and the longitudinal records allowing follow up into childhood. One weakness, inherent in observational studies, is confounding of the relationship between antibiotic prescribing and childhood cerebral palsy or epilepsy by maternal risk factors (such as parity which is not reliably recorded in UK primary care), and particularly by maternal infections that indicated antibiotic treatment.
We adjusted analyses for maternal risk factors including maternal infections for which there was evidence of an association with fetal neuro-damage (PNDI). We considered maternal infection to be a confounder in the analyses as there is evidence from numerous studies that certain maternal infections cause fetal neurological damage [32, 33] and mothers with infections are more likely to receive antibiotics. Failure to adjust for maternal infections can produce spurious associations that reflect the infection not the treatment. For example, two Danish population-based studies used antibiotic prescribing in pregnancy as a proxy for maternal infection. They reported associations between prenatal antibiotic prescribing and adverse neurological outcome in childhood, which are likely to reflect adverse effects of infections in pregnancy. [36, 37] We also endeavoured to minimise the potential adverse effects of antibiotics due to their beneficial effects on infection by conducting a pre-planned sensitivity analysis restricted to women with 'treated' and 'untreated' respiratory tract infections. Because respiratory tract infections diagnosed in primary-care are usually of viral aetiology [38] , any benefits due to antibiotic treatment of bacterial respiratory tract infection would be small or negligible, thereby increasing the chance of detecting potential adverse effects of antibiotic treatment. However, we were unable to measure infection severity-more severe infections would be linked to adverse fetal effects but would be more likely to be treated, thereby introducing bias in favour of an apparent harmful effect of antibiotics. Our comparison of different classes of antibiotics reduced confounding due to the indication for antibiotic treatment (i.e. infection) whereby an apparent association between prenatal antibiotics and adverse neurological outcome in childhood could result from the underlying infection which is a cause for both the antibiotic treatment and the brain damage manifesting as cerebral palsy and epilepsy. By examining only patients with an antibiotic prescription (and thus a likely infection) we were able to minimise such indication bias. This was particularly so for the comparison of macrolides versus penicillins as macrolides are used as alternative treatment for the same indications in penicillin-allergic patients. [21] Another limitation of the study is the measurement of antibiotic exposure. Firstly, we could not capture antibiotics prescribed by maternity services. The prevalence of antibiotics prescribed intrapartum and not recorded in primary-care is estimated to be less than 5% of pregnancies [28] but is not routinely documented in national data. Misclassification of women treated by maternity services as untreated in primary-care would likely have had negligible effect due to small numbers among women delivering at or after term. Secondly, we could not measure which women actually had their prescriptions dispensed and which women took antibiotics as prescribed. Few studies have quantified non-compliance in pregnancy, though this may be as high as 39%. [39] Our two-step approach to identifying children with cerebral palsy and epilepsy combined a sensitive algorithm with manual review of full medical records to ensure we only classified cases based on patterns of care in the longitudinal record that were consistent with cerebral palsy or epilepsy. Our criteria were highly specific so it is possible that we missed some cases. However, insensitive measurement of the outcome would not bias the relative effect. [40] Because antibiotics are frequently used in pregnancy, prescribing of antibiotics in primary-care is unlikely to have an impact on ascertainment of cerebral palsy or epilepsy and also unlikely to bias length of follow-up with the primary-care practice.
Using a composite outcome gave our analyses greater statistical power which enabled us to explore the impact of timing, number of courses and type of antibiotic prescribed. Disadvantages of using a composite outcome include the difficulty of determining specificity of adverse effects-for cerebral palsy and/or epilepsy separately. Our post-hoc analyses suggest the findings apply to epilepsy, but further studies are needed to explore a range of neurological outcomes.
Mechanisms
Our study was not designed to replicate the OCS II which focused on women in spontaneous preterm labour. However, it is intriguing that we found a similar association between maternal macrolide prescribing and cerebral palsy or epilepsy in children born at term. We propose several potential mechanisms for adverse effects of prenatal antibiotics-possibly arising from biases due to failure to account for 'damaged-survivors' and possibly through direct effects of macrolides. However, we would be cautious to draw a causal effect based on observational data.
First, prenatal antibiotic treatment could shift the spectrum of fetal neurological-damage caused by infection towards less severe outcomes-the 'damaged-survivor' hypothesis. This mechanism could manifest by increased survival and less severe neurological manifestations in survivors of treated versus untreated women. In OCS II, a shift may have affected a minority of infected and neurologically-damaged fetuses, resulting in insufficient imbalance in numbers of stillbirths, postnatal deaths or losses to follow-up (likely to be higher in more severely affected survivors [41] ), to reach statistical significance. A similar selection bias may have happened in our cohort study and may have masked any benefits of prenatal antibiotics.
Second, partially treated infection may prolong exposure of the fetal brain to inflammation, thereby increasing the risk of neuro-damage. This mechanism could be specific to macrolides if women stopped taking erythromycin because of gastrointestinal side-effects, [42, 43] or because of high rates of treatment failure from macrolide-resistant bacteria [44] or due to poor transplacental passage of macrolide antibiotics (in comparison to ampicillin, [45, 46] the most commonly prescribed penicillin in pregnancy in UK primary-care [47] ).
Third, macrolides may have a specific adverse effect on the fetus. There is a growing body of evidence that macrolides are associated with adverse outcomes-including cardiovascular events (including death) in adults [48] [49] [50] , cardiotoxicity [51] , and miscarriage [52] . Some studies have observed an association with macrolides and birth defects [53] [54] [55] , whilst others have not [56, 57] . The exact mechanism for harm is unclear, though arrhythmia resulting from inhibition of a cardiac potassium channel (IKr) and prolongation of the QT interval may play a role. [58] In animal studies, drugs which block the IKr channel (e.g. macrolide antibiotics [51] ) cause embryonic bradycardia, arrhythmia and cardiac arrest, even at concentrations that do not affect the maternal heart. [59] The resulting temporary hypoxia (from interrupted-/decreased oxygen supply) causes tissue damage. [60] Hypoxia in the first trimester is teratogenic [61] , resulting in an increased risk of transverse limb deficiencies and cardiac anomalies with IKr-blocking drugs (e.g. macrolides [53, 54] , clomipramine and paroxetine [62] , phenytoin [61] ). In addition to teratogenic effects, hypoxia is associated with failure of the fetus to grow and thrive in the uterus, [63] which is associated with cerebral palsy. [64] Hypoxia, in association with ischaemia and/or infection, is also thought to play a role in the aetiology of cerebral palsy and epilepsy. [65] [66] [67] 
Conclusions
We found no overall association between prescribing of any antibiotics during pregnancy and cerebral palsy or epilepsy in childhood. However, we found that prenatal prescribing of macrolides versus penicillins was associated with an increase in the relative risk of cerebral palsy or epilepsy in childhood, though the absolute risk remained low. This finding of harm associated with macrolide use in pregnancy is consistent with findings from the OCS II trial and with findings of adverse effects in other patient groups. 
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